New Results for Acute Hepatic Porphyria (AHP) Program Presented at ICPP 2024

24 Sep, 2024 New Results for Acute Hepatic Porphyria (AHP) Program Presented at ICPP 2024

New results from a post hoc subgroup analysis of the ENVISION Phase 3 study evaluating long-term outcomes in patients with acute hepatic porphyria (AHP) who were not attack-free after the first six months of GIVLAARI^® (givosiran) treatment were presented at The International Congress of Porphyrins and Porphyrias (ICPP 2024). Additional data presented at ICPP 2024 included demographic and clinical characteristics of patients with AHP enrolled in ELEVATE, an international, prospective, observational registry.

Ventura, et al. “Long-term clinical outcomes of patients with acute hepatic porphyria who were not attack-free after 6 months of givosiran treatment: a subgroup analysis of the phase 3 ENVISION study”

Sardh, et al. “Patient demographics and clinical characteristics at enrolment in ELEVATE, an international registry of acute hepatic porphyria”